Targeting Cholera Toxin

  • Author: Vikki Cantrill
  • Published: 08 June 2013
  • Copyright: Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: Organic and Biomolecular Chemistry/RSC Publishing
thumbnail image: Targeting Cholera Toxin

Cholera is a serious health problem in the developing world. Approximately 3–5 million cases occur annually. Although several treatments exist, drug resistance and mutations in cholera toxin (CT) mean new treatments are crucial.

CT has a pentameric binding-domain that recognizes cell surfaces, thereby infecting the host. If an inhibitor could prevent binding, disease onset may be avoidable. Han Zuilhof and colleagues, Wageningen University, The Netherlands, Università degli Studi di Parma, Italy, and National Research Council Canada, Canada, designed and synthesized a pentavalent inhibitor based on a calixarene core.

The core has small methoxy groups at the lower rim (pictured), and penta-saccharide units on the upper rim separated from the core by a long linker. In biological tests, the calixarene achieved picomolar potency (IC50 = 450 pM) making it one of the most potent known inhibitors of CT binding.

Article Views: 3313

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH